Arca
Skip to content
Tools
Tools

Bile acids

Small molecule in Homo sapiens that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 4
  • In phases 1 to 3: 0
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 3

Approved4

  • Cholestyramine
  • Colesevelam
  • Colestipol hydrochloride
  • Polidexide sulfate

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Bile acids sequestering agent.
        CholestyramineApprovedBristol-Myers SquibbOtherSequestering agent8
        ColesevelamApprovedCosette PharmaceuticalsOtherSequestering agent5
        Colestipol hydrochlorideApprovedPfizerOtherSequestering agent0
        Polidexide sulfateWithdrawnApproved—Small moleculeSequestering agent0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
        A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisCholestyraminePhase 3Not yet recruitingSanofiNov 12, 2026
        PFAS Clinical TrialCholestyraminePhase 2Not yet recruitingEmory UniversitySep 23, 2026
        Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans StudyColesevelamPhase 2Not yet recruitingUniversity of Rhode IslandMay 18, 2026
        Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)ColesevelamPhase 1 / Phase 2RecruitingUniversity of California, San FranciscoNov 10, 2025
        Metabolic Effects of Endogenous Bile Acids After Gastric Bypass SurgeryColesevelamEarly phase 1RecruitingHvidovre University HospitalApr 13, 2025
        LATAM LOWERS LDL-CCholestyraminePhase 4RecruitingNovartis PharmaceuticalsJul 15, 2024
        Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerCholestyraminePhase 1Active, not recruitingCity of Hope Medical CenterJun 12, 2024
        Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.ColesevelamPhase 1 / Phase 2RecruitingSt. Boniface HospitalJan 9, 2024
        Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisCholestyraminePhase 3Active, not recruitingSanofiNov 21, 2023
        Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female PatientsCholestyramineNot applicableRecruitingCentre Hospitalier Universitaire de NiceAug 1, 2023
        Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic MalignanciesCholestyraminePhase 1RecruitingCity of Hope Medical CenterJul 5, 2022
        Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibColesevelamPhase 2Active, not recruitingSpanish Breast Cancer Research GroupFeb 23, 2022
        Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American PatientsCholestyraminePhase 2Active, not recruitingCity of Hope Medical CenterAug 20, 2021

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364175, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.